Tormont50 Take : With a major change in the business model and a promising contract in hand, now is the time to take a closer look at MedX Health Corp.…
Mississauga, Ontario, February 28, 2024 – MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce they have successfully completed the pilot project with Health Partners…
MISSISSAUGA, ON — January 25, 2024 – MedX Health Corp. (“MedX” or the “Company”) (TSX VENTURE: MDX) is pleased to announce that it has appointed Dr. Paul Cohen, a board-certified dermatologist and Fellow of the Royal College of Physicians and Surgeons of Canada, as Medical Spokesperson. Dr. Cohen is also a diplomat of the American Board of Dermatology and is a member of numerous associations, including the Canadian Dermatological Association and the Toronto Dermatological Society…
Mississauga, ON, November 14, 2023. MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced today that, it has submitted for Final Acceptance from the TSXV and has closed the non-brokered Private Placement which was previously announced on August 30, 2023. The placement, to accredited investors, raised $1,020,000 by issuance of 14,571,428 units at $0.07per unit (“Unit”)….
MedX Health Corp., a speculative micro-cap stock with a current equity valuation of just $12 million, has developed its SIAscopeTM, a Class 2 medical scanning device which, used in conjunction with an HD camera, can scan suspicious – potentially cancerous – moles and lesions and penetrate two millimeters (mm) below the surface of the skin to accurately generate high quality images. See Figure 1 and 2. These images are then uploaded to MedX’s proprietary DermSecureTM telemedicine platform to be securely transmitted to dermatologists for assessment…
Stephen, who became a major investor in the company in recent months, and who joined the Board in April, 2023, brings extensive knowledge and years of financial management and entrepreneurial experience, and was instrumental in the introduction of the project with PharmaChoice which has just been launched in Canada,” said Ken McKay, Chairman of the MedX Board of Directors….
MedX Health Corp. (“MedX” or the “Company“) (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding for the launch of a new commercialization pilot project (the “Pilot Project”) with PharmaChoice Canada (“PharmaChoice”), one of Canada’s fastest‐growing pharmacy groups
Si vous avez besoin de plus d'informations sur nos services ou notre vision d'entreprise, veuillez nous contacter et nous vous mettrons en relation avec le membre approprié de notre équipe qui pourra mieux vous servir !